Radio-opaque ethylcellulose-ethanol is a safe and efficient sclerosing agent for venous malformations.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer International Country of Publication: Germany NLM ID: 9114774 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1084 (Electronic) Linking ISSN: 09387994 NLM ISO Abbreviation: Eur Radiol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Berlin : Springer International, c1991-
    • Subject Terms:
      Sclerotherapy*/methods; Cellulose/*analogs & derivatives ; Ethanol/*therapeutic use ; Sclerosing Solutions/*therapeutic use ; Vascular Malformations/*therapy ; Veins/*abnormalities; Adolescent ; Adult ; Aged ; Cellulose/therapeutic use ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Klippel-Trenaunay-Weber Syndrome/therapy ; Lymphatic Vessels/abnormalities ; Male ; Middle Aged ; Prospective Studies ; Treatment Outcome ; Vascular Malformations/diagnosis ; Veins/pathology ; Young Adult
    • Abstract:
      Objective: To evaluate the efficacy and safety of gelified ethanol, a newly developed sclerosing agent for slow-flow vascular malformations.
      Methods: Seventy-nine sclerotherapy procedures were performed on 44 patients with 37 venous malformations, 2 glomuvenous malformations, 2 lymphatic malformations, 2 lymphatico-venous malformations, and 1 Klippel-Trenaunay syndrome. The median injected volume was 1.00 mL/site of injection. Effects of sclerotherapy on pain, functional and cosmetic disturbance were statistically evaluated with a final result score. Local and systemic complications were recorded.
      Results: The mean Visual Analogue Scores were 5.20  ±  2.81 before and 1.52  ±  1.25 after treatment (p < 0.001). Functional and aesthetic improvement was achieved in 31/35 patients (89%) and in 33/41 (80%), respectively. Minor local side effects included necrosis with or without issue of ethylcellulose, palpable residue, and hematoma. No systemic side-effects occurred.
      Conclusion: Per mL used, radio-opaque gelified ethanol is at least as effective as absolute ethanol. No systemic complication was observed, as only a low dose of ethanol was injected. Indications for sclerotherapy can be widened to areas with higher risk for local side effects (hands and periocular region), as ethanol is trapped in the lesion. Careful injection procedure is though necessary, because only a limited amount of ethylcellulose can be used per puncture. Key Points • Development of a new sclerosing agent for venous malformations. • Interesting novel way to deliver alcohol to slow-flow vascular malformations. • Alcohol-based with less local and systemic side-effects.
    • References:
      Scand J Plast Reconstr Surg Hand Surg. 1994 Dec;28(4):279-84. (PMID: 7899838)
      AJR Am J Roentgenol. 2010 May;194(5):W439-44. (PMID: 20410391)
      Rev Stomatol Chir Maxillofac. 2000 Jan;101(1):30-2. (PMID: 10738751)
      Hum Mol Genet. 2009 Apr 15;18(R1):R65-74. (PMID: 19297403)
      Eur J Radiol. 2004 Dec;52(3):283-7. (PMID: 15544907)
      J Vasc Surg. 2008 Nov;48(5):1286-91. (PMID: 18829241)
      Phlebology. 2010 Oct;25(5):224-35. (PMID: 20870869)
      Cell. 1996 Dec 27;87(7):1181-90. (PMID: 8980225)
      J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):253-62. (PMID: 16517770)
      J Vasc Interv Radiol. 2004 May;15(5):431-45. (PMID: 15126652)
      Radiographics. 1990 Sep;10(5):787-96. (PMID: 2217971)
      Radiology. 1989 Mar;170(3 Pt 2):1059-66. (PMID: 2916057)
      J Vasc Interv Radiol. 2001 May;12(5):595-600. (PMID: 11340138)
      Arch Dermatol. 2003 Nov;139(11):1409-16. (PMID: 14623700)
      Arch Dermatol. 2004 Aug;140(8):971-6. (PMID: 15313813)
      Cardiovasc Intervent Radiol. 1997 Jul-Aug;20(4):268-73. (PMID: 9211773)
      Plast Reconstr Surg. 1982 Mar;69(3):412-22. (PMID: 7063565)
      Paediatr Anaesth. 2006 Mar;16(3):343-6. (PMID: 16490104)
      Ann Fr Anesth Reanim. 2001 Jun;20(6):556-8. (PMID: 11471504)
      J Radiol. 2004 Feb;85(2 Pt 1):107-16. (PMID: 15094624)
      Interv Neuroradiol. 2004 Jun 29;10(2):113-27. (PMID: 20587223)
      Cir Pediatr. 2006 Apr;19(2):77-80. (PMID: 16846128)
      Acad Radiol. 2009 Aug;16(8):988-96. (PMID: 19394874)
      Radiology. 2000 Oct;217(1):127-32. (PMID: 11012433)
      Phlebology. 2007;22(6):264-75. (PMID: 18274334)
      J Vasc Surg. 2008 Mar;47(3):578-84. (PMID: 18295109)
      J Vasc Surg. 2001 Apr;33(4):904-6. (PMID: 11296353)
      Nat Genet. 2009 Jan;41(1):118-24. (PMID: 19079259)
      Interv Neuroradiol. 2002 Sep 30;8(3):321-4. (PMID: 20594492)
      J Vasc Interv Radiol. 2009 Jan;20(1):39-45; quiz 45. (PMID: 19028113)
      Radiology. 2002 Jun;223(3):639-44. (PMID: 12034929)
      Neuroradiology. 2000 Sep;42(9):692-6. (PMID: 11071446)
      Plast Reconstr Surg. 1999 Jul;104(1):1-11; discussion 12-5. (PMID: 10597669)
      Masui. 2004 Jun;53(6):645-9. (PMID: 15242036)
      J Am Acad Dermatol. 2008 Aug;59(2):355-6. (PMID: 18638637)
      Cardiovasc Surg. 2002 Dec;10(6):523-33. (PMID: 12453680)
      Arch Dermatol. 2009 Nov;145(11):1239-44. (PMID: 19917952)
      Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R140-9. (PMID: 17670762)
      J Vasc Surg. 1997 Nov;26(5):838-44. (PMID: 9372823)
      Arch Dermatol. 2008 Jul;144(7):873-7. (PMID: 18645138)
    • Accession Number:
      0 (Sclerosing Solutions)
      3K9958V90M (Ethanol)
      7Z8S9VYZ4B (ethyl cellulose)
      9004-34-6 (Cellulose)
    • Publication Date:
      Date Created: 20110809 Date Completed: 20120227 Latest Revision: 20211020
    • Publication Date:
      20221213
    • Accession Number:
      10.1007/s00330-011-2213-4
    • Accession Number:
      21822948